Tibetans bat for Liu Xioabo’s freedom to choose his medical treatment

By Lobsang Tenchoe

DHARAMSALA, July 12: Gu-Chu-Sum Movement Association of Tibet and Students for a Free Tibet (SFT)- India condemned China for the treatment it meted out to the country’s only Nobel Peace Prize laureate, Liu Xiaobo.

The two Dharamsala-based Tibetan NGOs held an event today in solidarity with Liu Xiaobo and demanded the Chinese government to guarantee him the freedom to choose where and what medical treatment he wishes to receive as China presses to object to the dying dissident’s treatment abroad.

19988799_1588088107902260_1168100075_n“As an organization of the former political prisoners of Tibet in exile, we can empathize with the immense mental and physical torture one goes through in Chinese prison, specifically those courageous individuals who dare to voice their discontentment and criticism against the Chinese communist government,” Lhagyari Namgyal Dolkar, President of Gu-Chu-Sum Movement Association of Tibet said.

“We demand the right to life for Liu Xiaobo. Chinese government should be held accountable for any case of mishap. The international leaders and the UN need to intervene in the matter and pressure China,” she added.

Activists from the two groups staged a skit wherein five activists held pictures of the Chinese activist inscribed with a year which marks a significant development in his life. The activists took turns to explain the significance of the year inscribed on the picture they held.

“Liu Xiaobo is a Chinese democracy activist and Nobel Laureate who has been critical of Chinese government law. The Chinese Communist Party’s treatment of Liu Xioabo is a clear evidence of their draconian and arbitrary rule. We demand to guarantee Liu Xioabo the freedom to choose where and what medical treatment to be received,” Tenzin Tselha, National Director of SFT-India said in a press statement.

Share on Facebook0Tweet about this on TwitterShare on Google+0Share on LinkedIn0Share on Tumblr0Email this to someone

Comments are closed.